HRP20150613T1 - Sol benzojeve kiseline otamiksabana - Google Patents
Sol benzojeve kiseline otamiksabana Download PDFInfo
- Publication number
- HRP20150613T1 HRP20150613T1 HRP20150613TT HRP20150613T HRP20150613T1 HR P20150613 T1 HRP20150613 T1 HR P20150613T1 HR P20150613T T HRP20150613T T HR P20150613TT HR P20150613 T HRP20150613 T HR P20150613T HR P20150613 T1 HRP20150613 T1 HR P20150613T1
- Authority
- HR
- Croatia
- Prior art keywords
- benzoic acid
- amino
- methyl
- acid salt
- imino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305348 | 2011-03-29 | ||
| US201161500342P | 2011-06-23 | 2011-06-23 | |
| EP12711858.6A EP2691371B1 (en) | 2011-03-29 | 2012-03-27 | Benzoic acid salt of otamixaban |
| PCT/EP2012/055364 WO2012130821A1 (en) | 2011-03-29 | 2012-03-27 | Benzoic acid salt of otamixaban |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150613T1 true HRP20150613T1 (hr) | 2015-07-17 |
Family
ID=44065390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150613TT HRP20150613T1 (hr) | 2011-03-29 | 2012-03-27 | Sol benzojeve kiseline otamiksabana |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8993602B2 (enExample) |
| EP (1) | EP2691371B1 (enExample) |
| JP (1) | JP5959617B2 (enExample) |
| KR (1) | KR101852226B1 (enExample) |
| CN (1) | CN103562183B (enExample) |
| AU (1) | AU2012234325B2 (enExample) |
| BR (1) | BR112013025105A2 (enExample) |
| CA (1) | CA2830965C (enExample) |
| CY (1) | CY1116659T1 (enExample) |
| DK (1) | DK2691371T3 (enExample) |
| ES (1) | ES2539236T3 (enExample) |
| HR (1) | HRP20150613T1 (enExample) |
| IL (1) | IL228574A (enExample) |
| MX (1) | MX2013011266A (enExample) |
| MY (1) | MY161396A (enExample) |
| PL (1) | PL2691371T3 (enExample) |
| PT (1) | PT2691371E (enExample) |
| RU (1) | RU2597423C2 (enExample) |
| SG (1) | SG193612A1 (enExample) |
| SI (1) | SI2691371T1 (enExample) |
| WO (1) | WO2012130821A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013024801A2 (pt) | 2011-03-29 | 2016-12-20 | Sanofi Sa | formulações de otamixaban com estabilidade aprimorada |
| CN106565698B (zh) * | 2016-08-15 | 2019-03-08 | 南京帕隆材料科技有限公司 | 取代噻唑类衍生物及其制备方法和用途 |
| CN106518859B (zh) * | 2016-08-15 | 2019-01-18 | 南京帕隆材料科技有限公司 | 噻唑类衍生物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424334A (en) | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
| US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| CA2241904C (en) * | 1996-01-02 | 2004-12-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| GB0108903D0 (en) * | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| NZ599556A (en) * | 2007-05-02 | 2013-10-25 | Portola Pharm Inc | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| JP2013500298A (ja) * | 2009-07-29 | 2013-01-07 | サノフイ | 高齢かつ腎障害の非ｓｔ上昇型心筋梗塞患者の処置のためのオタミキサバン |
-
2012
- 2012-03-27 MX MX2013011266A patent/MX2013011266A/es active IP Right Grant
- 2012-03-27 EP EP12711858.6A patent/EP2691371B1/en active Active
- 2012-03-27 SG SG2013071766A patent/SG193612A1/en unknown
- 2012-03-27 MY MYPI2013003459A patent/MY161396A/en unknown
- 2012-03-27 KR KR1020137028416A patent/KR101852226B1/ko not_active Expired - Fee Related
- 2012-03-27 JP JP2014501569A patent/JP5959617B2/ja active Active
- 2012-03-27 RU RU2013148005/04A patent/RU2597423C2/ru not_active IP Right Cessation
- 2012-03-27 CA CA2830965A patent/CA2830965C/en not_active Expired - Fee Related
- 2012-03-27 BR BR112013025105A patent/BR112013025105A2/pt not_active Application Discontinuation
- 2012-03-27 ES ES12711858.6T patent/ES2539236T3/es active Active
- 2012-03-27 DK DK12711858.6T patent/DK2691371T3/da active
- 2012-03-27 WO PCT/EP2012/055364 patent/WO2012130821A1/en not_active Ceased
- 2012-03-27 US US14/008,332 patent/US8993602B2/en active Active
- 2012-03-27 PT PT127118586T patent/PT2691371E/pt unknown
- 2012-03-27 HR HRP20150613TT patent/HRP20150613T1/hr unknown
- 2012-03-27 AU AU2012234325A patent/AU2012234325B2/en not_active Ceased
- 2012-03-27 SI SI201230219T patent/SI2691371T1/sl unknown
- 2012-03-27 PL PL12711858T patent/PL2691371T3/pl unknown
- 2012-03-27 CN CN201280026534.0A patent/CN103562183B/zh active Active
-
2013
- 2013-09-29 IL IL228574A patent/IL228574A/en active IP Right Grant
-
2015
- 2015-06-17 CY CY20151100521T patent/CY1116659T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103562183A (zh) | 2014-02-05 |
| PT2691371E (pt) | 2015-07-20 |
| US20140024684A1 (en) | 2014-01-23 |
| DK2691371T3 (da) | 2015-06-22 |
| SI2691371T1 (sl) | 2015-07-31 |
| AU2012234325B2 (en) | 2016-08-11 |
| HK1189584A1 (en) | 2014-06-13 |
| CN103562183B (zh) | 2015-12-23 |
| JP2014509622A (ja) | 2014-04-21 |
| BR112013025105A2 (pt) | 2017-06-06 |
| IL228574A0 (en) | 2013-12-31 |
| EP2691371A1 (en) | 2014-02-05 |
| CA2830965C (en) | 2019-04-09 |
| KR101852226B1 (ko) | 2018-04-25 |
| WO2012130821A1 (en) | 2012-10-04 |
| CA2830965A1 (en) | 2012-10-04 |
| IL228574A (en) | 2015-07-30 |
| MX2013011266A (es) | 2014-03-27 |
| SG193612A1 (en) | 2013-11-29 |
| CY1116659T1 (el) | 2017-03-15 |
| US8993602B2 (en) | 2015-03-31 |
| RU2013148005A (ru) | 2015-05-10 |
| MY161396A (en) | 2017-04-14 |
| EP2691371B1 (en) | 2015-03-18 |
| RU2597423C2 (ru) | 2016-09-10 |
| KR20140022851A (ko) | 2014-02-25 |
| ES2539236T3 (es) | 2015-06-29 |
| JP5959617B2 (ja) | 2016-08-02 |
| PL2691371T3 (pl) | 2015-08-31 |
| AU2012234325A1 (en) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150704T1 (hr) | Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka | |
| HRP20180804T1 (hr) | Inhibitori dnk-pk | |
| MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| HRP20150531T1 (hr) | Pirazolilaminopiridini kao inhibitori fak | |
| JP2015517552A5 (enExample) | ||
| AR097159A1 (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
| ME02322B (me) | Kinazni inhibitor koji reguliše signalni put apoptoze | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| CL2013002227A1 (es) | Sales de acido de (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, util en el tratamiento de enfermedades del snc. (divisional de la sol. 2271-08). | |
| JP2015145426A5 (enExample) | ||
| HRP20140613T1 (hr) | Novi intermedijer i postupak koji je koristan za dobivanje {2-[1-(3,5-bi-trifluorometil-benzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-klorofenil)-metanona | |
| HRP20240197T1 (hr) | Farmaceutski pripravak koji sadrži protuvirusni derivat dihidrokinazolina koji ima konfiguraciju s na položaju 4 | |
| FI2970123T4 (fi) | Omekamtiivimekarbiilin kiteinen dihydrokloridihydraattisuola ja menetelmä sen valmistamiseksi | |
| IN2014DN11207A (enExample) | ||
| CO7051030A2 (es) | Formulaciones farmacéuticas novedosas | |
| MY170437A (en) | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide | |
| WO2015011119A3 (en) | Salts of dasatinib in amorphous form | |
| HRP20210044T1 (hr) | Farmaceutski prihvatljive soli beta-gvanidinopropionske kiseline sa poboljšanim svojstvima i njihova upotreba | |
| JP2015509972A5 (enExample) | ||
| RU2017143849A (ru) | Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения | |
| JP2014509621A5 (enExample) | ||
| ME02199B (me) | Nova farmaceutska formulacija za tretman gljivičnih infekcija | |
| FI3659627T3 (fi) | Polyfosfaattifunktionalisoituja epäorgaanisia nanopartikkeleita hemostaattisina koostumuksina ja käyttömenetelmiä | |
| WO2015011120A3 (en) | Salts of dasatinib in crystalline form | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 |